Vizsgálati helyszín
Gyoengyosi Bugat Pal Koerhaz
Gyongyos, 3200, MagyarországEU-13 felzárkózó országMég nincs intézményhez kötve
- 15futó vizsgálat
- 6lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 21 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis15 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Toboroz8 vizsgálat
- Lezárult6 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Még nem toboroz2 vizsgálat
- Fő szponzor
- Neurocrine Biosciences4 vizsgálat
- Amgen Inc.2 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- Janssen Research & Development, LLC2 vizsgálat
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 vizsgálat
- és még 8
Futó vizsgálatok
Toboroz
Efficacy and safety of a combined therapy in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial (ARIEL)
2025-521985-82-00· 2. fázis· Woerwag Pharma GmbH & Co. KG· Forrás
Toboroz
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Fut, nem toboroz
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· 2. fázis· Abivax S.A.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· 3. fázis· Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· 2. fázis· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Forrás
Toboroz
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Lezárult
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Lezárult
A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
2024-513569-38-00· 2/3. fázis· Arena Pharmaceuticals Inc.· Forrás
Lezárult
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
NCT02914535· 3. fázis· Alfasigma S.p.A.· Forrás
Hibát jelzek